Trial Profile
An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 16 Jan 2024
Price :
$35
*
At a glance
- Drugs VMD-928 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors VM Oncology
- 10 Jan 2024 Planned End Date changed from 1 Jun 2025 to 1 Dec 2025.
- 10 Jan 2024 Planned primary completion date changed from 1 Dec 2024 to 1 Jun 2025.
- 08 May 2023 Planned End Date changed from 1 Jun 2024 to 1 Jun 2025.